Vaccinex Inc (NASDAQ:VCNX) was the target of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 113,900 shares, a growth of 8.3% from the January 15th total of 105,200 shares. Currently, 2.4% of the company’s shares are sold short. Based on an average daily volume of 14,000 shares, the short-interest ratio is currently 8.1 days.
Vaccinex stock opened at $5.92 on Friday. Vaccinex has a 52 week low of $3.77 and a 52 week high of $12.23. The company’s 50 day moving average price is $5.78 and its two-hundred day moving average price is $5.60. The stock has a market cap of $91.65 million, a P/E ratio of -1.14 and a beta of 1.37.
Vaccinex (NASDAQ:VCNX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.10. Vaccinex had a negative return on equity of 585.69% and a negative net margin of 4,740.03%. The firm had revenue of $0.40 million for the quarter. As a group, sell-side analysts expect that Vaccinex will post -2.61 EPS for the current fiscal year.
A number of research firms recently issued reports on VCNX. Zacks Investment Research downgraded shares of Vaccinex from a “buy” rating to a “hold” rating in a research report on Wednesday, January 29th. ValuEngine lowered shares of Vaccinex from a “buy” rating to a “hold” rating in a research note on Friday, January 24th.
In other Vaccinex news, Director Albert Friedberg purchased 982,318 shares of the business’s stock in a transaction on Thursday, January 23rd. The shares were purchased at an average cost of $7.03 per share, for a total transaction of $6,905,695.54. Also, CEO Maurice Zauderer acquired 98,231 shares of Vaccinex stock in a transaction dated Thursday, January 23rd. The shares were bought at an average cost of $7.03 per share, with a total value of $690,563.93. Company insiders own 69.90% of the company’s stock.
An institutional investor recently raised its position in Vaccinex stock. Oppenheimer & Co. Inc. increased its position in Vaccinex Inc (NASDAQ:VCNX) by 82.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 28,900 shares of the company’s stock after purchasing an additional 13,100 shares during the quarter. Oppenheimer & Co. Inc. owned approximately 0.19% of Vaccinex worth $207,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 10.04% of the company’s stock.
Vaccinex Company Profile
Vaccinex, Inc, a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease.
Featured Story: Pattern Day Trader
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.